Blue Trust Inc. Decreases Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

Blue Trust Inc. trimmed its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 43.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,055 shares of the medical device company’s stock after selling 826 shares during the period. Blue Trust Inc.’s holdings in Cooper Companies were worth $97,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in COO. Ashton Thomas Securities LLC purchased a new position in Cooper Companies in the 3rd quarter valued at about $25,000. Byrne Asset Management LLC purchased a new position in Cooper Companies in the 4th quarter valued at about $33,000. Covestor Ltd boosted its position in Cooper Companies by 144.9% in the 3rd quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock valued at $37,000 after buying an additional 200 shares during the last quarter. Brown Brothers Harriman & Co. boosted its position in Cooper Companies by 191.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 419 shares of the medical device company’s stock valued at $46,000 after buying an additional 275 shares during the last quarter. Finally, West Financial Advisors LLC purchased a new position in Cooper Companies in the 4th quarter valued at about $49,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on COO shares. Morgan Stanley cut their target price on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a research note on Friday, December 6th. Wells Fargo & Company upped their target price on shares of Cooper Companies from $115.00 to $118.00 and gave the company an “overweight” rating in a research note on Friday, December 6th. Citigroup cut their target price on shares of Cooper Companies from $116.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, December 6th. StockNews.com lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday, December 6th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Cooper Companies currently has an average rating of “Moderate Buy” and an average price target of $117.00.

Cooper Companies Price Performance

COO opened at $88.48 on Friday. The firm has a market cap of $17.66 billion, a price-to-earnings ratio of 45.37, a price-to-earnings-growth ratio of 2.25 and a beta of 1.00. The Cooper Companies, Inc. has a fifty-two week low of $84.76 and a fifty-two week high of $112.38. The company’s 50-day moving average price is $92.94 and its 200 day moving average price is $99.60. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, December 5th. The medical device company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.00 by $0.04. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the business earned $0.87 earnings per share. Cooper Companies’s revenue was up 9.8% compared to the same quarter last year. As a group, sell-side analysts expect that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.